Codexis, Inc. Q3 2026 Earnings Conference Call - CODEXIS INC

Explicit Guidance:

• Full-year 2026 revenue guidance reiterated at $72 million to $76 million.
• Full-year 2026 gross margin anticipated in the low 70s percent range.
• Cash runway expected to be sufficient to fund planned operations and capital expenditures through 2028.
• Debt structure established via a new $60 million term loan (drawn $42.5 million) with 48 months of interest-only payments followed by a 12-month amortization period.
• Expectation of seven clinical trial data readouts within the next two years for enzymes in the small-molecule biocatalysis business.

Business-Segment Outlook:

• Ecosynthesis Platform: Advancing from 100-gram scale toward 500-gram production in the coming months, with a path to kilo-scale readiness via fragment ligation strategies.
• Small-Molecule Biocatalysis: Revenue for the first nine months of 2026 up 78.5% year-over-year, led by CDX049; pipeline includes 12 programs in Phase II/III with robust commercialization potential for three recently approved drugs.
• Technology Transfer: First planned transfer of Ecosynthesis technology into a large biopharmaceutical customer's pilot plant to assess in-house production capability; currently conducting three ongoing small-scale evaluations with CDMOs, with two additional new CDMO engagements.
• Product Capabilities: Platform expansion to include efficient attachment of tissue-targeting molecules within standard workflows; demonstrated 3- to 4-fold increase in potency via stereochemical control compared to random synthesis.

Market and Competitive Outlook:

• Industry dialogue shifting from "proof of concept" to deployment and implementation in development pipelines.
• Anticipated share shifts as customers move from solid-phase chemistry to enzymatic approaches to overcome physical scale limitations (currently capped at 7–10 kilos/batch for chemical synthesis) and access metric ton-scale manufacturing.
• Targeting large population indications for siRNA therapeutics requiring cost-effective, high-volume manufacturing.
• CDMOs (including those not currently in the space) viewing Ecosynthesis as a capital-efficient entry strategy (approx. 70% more capital efficient than existing infrastructure) to capture market share in the oligonucleotide sector.

Macro / Industry Outlook:

• Recognition that traditional manufacturing methods are insufficient to support the commercial aspirations of RNAi medicines.
• Expectation that regulatory engagement (specifically with the FDA Emerging Technologies team) will focus on comparability arguments for stereochemical control versus traditional solid-phase chemistry.
• No specific macroeconomic variables (rates, FX, tariffs) explicitly quantified as direct drivers; focus remains on technological obsolescence of current chemical synthesis at scale.

Strategic Initiatives:

• GMP Facility: Scheduled to begin construction of a new GMP production facility within the current year.
• Supply Chain: Advancement of the Ecosynthesis raw materials supply chain to support larger scale operations.
• Commercial Expansion: Multiple commercial initiatives nearing final stages of negotiation; management aims to sign higher-value contracts and innovative licensing deals in 2027.
• Partnerships: Active engagement with a pioneer in the field for a feasibility study on stereo-defined fragments and a large biopharma partner for late-stage asset ligation and pilot-scale assessment.

Risks and Headwinds to Outlook:

• Execution Risk: Successful translation from 500-gram to kilo-scale and commercial GMP deployment remains unproven at full scale.
• Regulatory Uncertainty: Dependence on FDA alignment for comparability arguments and specifications regarding enzyme and siRNA products generated by the platform.
• Timeline Variability: Difficulty in predicting exact timing for the conversion of evaluations into definitive commercial agreements or licensing deals.
• Technology Scaling: While process understanding is robust, the predictive relationship between scale and product performance must be continuously validated as batch sizes increase.

Management Tone on the Future:

• Confidence Level: High; management describes the shift in industry dialogue as "exciting" and "forward-looking," moving from curiosity to serious deployment planning.
• Key Hedges: Emphasis on "industrializing the technology" and "closing out the year with momentum" suggests a focus on execution risk mitigation.
• Change vs. Prior: Shift from technical feasibility validation to process economics and commercial viability; confidence in the platform's ability to disrupt the landscape and enable annual dosing or reduced COGS via increased potency.
• Sentiment: Optimistic about "proving success" through 2027 revenue targets and new deal announcements.

Miscellaneous:

• FDA Interaction: Successfully completed a constructive meeting in late September regarding enzyme specifications, siRNA product specifications, and comparability arguments for stereochemical control.
• Equity Offering: Completed in early Q3 2026, raising $25 million in net proceeds.
• Cost Control: R&D expenses down $1.3 million YoY in Q3; SG&A down $1.1 million YoY due to headcount reduction and lower stock-based compensation.